Letter to the EditorPeripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
Section snippets
Contributors
Fernanda F. Peres, Rodrigo A. Bressan, Antonio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abilio designed the study. Authors Fernanda F. Peres, Mariana C. Diana, Mayra A. Suiama, Verônica Justi and Valéria Almeida conducted the experiments, statistical analysis and managed the literature search. Authors Fernanda F. Peres and Vanessa C. Abilio wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.
Conflict of interest
J.E.H., A.W.Z. and J.A.C. are co-inventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023”.
References (8)
- et al.
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2013) - et al.
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats
Behav. Brain Res.
(2011) - et al.
A review of 25 years of the social interaction test
Eur. J. Pharmacol.
(2003) - et al.
To model a psychiatric disorder in animals: schizophrenia as a reality test
Neuropsychopharmacology
(2000)
Cited by (22)
Toll-like receptor signalling as a cannabinoid target
2024, Biochemical PharmacologyPhytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
2021, Pharmacological ResearchCitation Excerpt :Further studies into the impact of CBD on altered DAergic signalling may shed light on the mechanisms underlying its therapeutic effects on SCZ-related disorders. Additional potential mechanisms in the CBD effects seem to involve 5-HTergic system both in term of increased 5-HT turnover in the PFC [156] and of 5-HT1A activation [209]. However, the potential involvement of TRPV1 as well as of GPR55 in the antipsychotic CBD activity has been also suggested [199].
Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models
2020, Neuroscience and Biobehavioral ReviewsCitation Excerpt :As only male offspring were utilised within these MIA x ACE models, sex differences are yet to be determined with the combination of these risk factors. With regard to CBD, Peres et al. (2016) investigated the effects of MIA x ACE via CBD as a potential preventative treatment for the behavioural deficits induced by MIA, specifically locomotion and social interaction. When administered in periadolescence, CBD was found to reverse increased locomotion in MIA x ACE animals in adulthood, however CBD had no effect on social deficits induced by MIA.
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment
2020, Biochemical PharmacologyCitation Excerpt :Among new candidate compounds, accumulating evidence points towards cannabidiol (CBD), the most abundant non-euphoric phytocannabinoid, endowed with a favourable pharmacological profile, as an alternative treatment option for those SCZ symptoms that are not satisfactorily ameliorated by current theraphies [8,9]. In agreement with the hypothesis that early intervention at a critical period (the so-called window of opportunity) may be effective in circumventing the transition to SCZ [10], it has been observed that peripubertal CBD treatment prevents the development of SCZ-like alterations in animal models at adulthood [11,12]. In particular, CBD regulates the mesolimbic DAergic system, which may, at least in part, underlie its behavioral effects [13].